1
|
Tanay MA, Diez de Los Rios de la Serna C, Boland V, Lopes AMDS, Wingfield K, Chircop D, Dornan M, Suchodolska G, Yıldız Aytaç G, Kurt B, Colomer-Lahiguera S. Patient and public involvement in research: Reflections and experiences of doctoral cancer nurse researchers in Europe. Eur J Oncol Nurs 2023; 64:102351. [PMID: 37290166 DOI: 10.1016/j.ejon.2023.102351] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/07/2022] [Revised: 01/23/2023] [Accepted: 05/21/2023] [Indexed: 06/10/2023]
Abstract
PURPOSE Early career researchers lack guidance about patient and public involvement (PPI). The overall aim of the study was to explore the knowledge and experiences of using PPI in research among doctoral students who are registered nurses. METHODS This qualitative study included findings generated from reflective essays and focus groups involving ten registered cancer nurses who are undertaking doctoral research. The study has two stages of data collection. Participants initially wrote a reflective essay using a set of guiding questions to structure a response which was subsequently analysed. Two focus groups were then conducted to provide further insight into the themes identified in the reflective essays. Reflective thematic analysis was used to identify, name, and define the final themes. RESULTS There were ten participants from seven countries and were at various stages of their doctoral study. Analysis of data from reflective essays (n = 10) and focus groups (n = 2) identified four themes namely, (a) evolving recognition and appreciation of PPI, (b) embracing PPI and impact on doctoral studies, (c) the influence of the research environment, and (d) the need to empower doctoral students to integrate PPI in their research journey. CONCLUSION Participants reported differing experiences of PPI awareness showing disparity in guidance about PPI for junior researchers across Europe. We recommend provision of early PPI training for doctoral students to support and encourage involvement of patients and the public in their research. Opportunities for sharing PPI experiences to help improve PPI culture in research environments that support doctoral students should be explored.
Collapse
Affiliation(s)
- Mary Anne Tanay
- Florence Nightingale Faculty of Nursing, Midwifery and Palliative Care, King's College London, United Kingdom.
| | | | - Vanessa Boland
- School of Nursing and Midwifery, Trinity College Dublin, Ireland
| | - André Manuel Da Silva Lopes
- Institute of Higher Education and Research in Healthcare-IUFRS, University of Lausanne, Lausanne University Hospital, Switzerland
| | - Karen Wingfield
- School of Healthcare Sciences, Cardiff University, United Kingdom
| | - Daren Chircop
- School of Health Sciences, University of Southampton, United Kingdom
| | - Mark Dornan
- Institute of Nursing and Health Research, Ulster University, United Kingdom
| | - Grażyna Suchodolska
- Department of Oncology & Radiotherapy, Faculty of Medicine, Medical University of Gdańsk, Poland
| | - Gülşah Yıldız Aytaç
- Faculty of Nursing, Psychiatric Nursing Department, Hacettepe University, Turkey
| | - Berna Kurt
- Faculty of Nursing, Internal Medicine Nursing Department, Hacettepe University, Turkey
| | - Sara Colomer-Lahiguera
- Institute of Higher Education and Research in Healthcare-IUFRS, University of Lausanne, Lausanne University Hospital, Switzerland
| |
Collapse
|
2
|
Da Silva Lopes AM, Colomer-Lahiguera S, Mederos Alfonso N, Aedo-Lopez V, Spurrier-Bernard G, Tolstrup LK, Pappot H, Aspeslagh S, Rogiers A, Neyns B, Haanen JB, Mitchell SA, Addeo A, Michielin O, Eicher M. Patient-reported outcomes for monitoring symptomatic toxicities in cancer patients treated with immune-checkpoint inhibitors: A Delphi study. Eur J Cancer 2021; 157:225-237. [PMID: 34536946 DOI: 10.1016/j.ejca.2021.08.026] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2021] [Revised: 08/12/2021] [Accepted: 08/13/2021] [Indexed: 11/26/2022]
Abstract
BACKGROUND Immune-related adverse events (IrAEs) associated with the use of immune checkpoint inhibitors (ICIs) may not be fully covered by existing measures like the PRO-CTCAE™. Selecting PRO-CTCAE™ items for monitoring symptomatic adverse events is hindered by the heterogeneity and complexity of IrAEs, and no standardised selection process exists. We aimed to reach expert consensus on the PRO-CTCAE™ symptom terms relevant for cancer patients receiving ICIs and to gather preliminary expert opinions about additional symptom terms reflecting ICI symptomatic toxicities. Additionally, we gathered expert consensus about a core set of priority symptom terms for prospective surveillance and monitoring. DESIGN This Delphi study involved an international panel of experts (n = 6 physicians; n = 3 nurses, n = 1 psychiatrist and n = 1 patient advocates). Experts prioritised the relevance and importance of symptom terms to monitor in patients treated with ICIs. RESULTS Experts reached a consensus on the relevance of all (n = 80) PRO-CTCAE™ Symptom Terms. Consensus on the importance of these symptom terms for prospective monitoring in patients receiving ICIs was reached for 81% (n = 65) of these terms. Additional symptoms terms (n = 56) were identified, with a consensus that 84% (47/56) of these additional symptom terms should also be considered when monitoring symptomatic IrAEs. CONCLUSION This study identified a prioritised list of symptom terms for prospective surveillance for symptomatic IrAEs in patients receiving ICI treatment. Our results indicate the need to strengthen the validity of PRO measures used to monitor patients receiving ICIs. While these results provided some support for the content validity of the PRO CTCAE™ and resulted in a preliminary set of salient symptomatic adverse events related to the use of ICIs, broader international agreement and patient involvement are needed to further validate our initial findings.
Collapse
Affiliation(s)
- André Manuel Da Silva Lopes
- Department of Oncology, Lausanne University Hospital (CHUV), Lausanne, Switzerland; Institute of Higher Education and Research in Healthcare, Faculty of Biology and Medicine, University of Lausanne and Lausanne University Hospital, Lausanne, Switzerland
| | - Sara Colomer-Lahiguera
- Department of Oncology, Lausanne University Hospital (CHUV), Lausanne, Switzerland; Institute of Higher Education and Research in Healthcare, Faculty of Biology and Medicine, University of Lausanne and Lausanne University Hospital, Lausanne, Switzerland
| | | | - Veronica Aedo-Lopez
- Department of Oncology, Lausanne University Hospital (CHUV), Lausanne, Switzerland
| | | | - Lærke Kjær Tolstrup
- Department of Oncology, Research Unit, Odense University Hospital, Odense, Denmark
| | - Helle Pappot
- Department of Oncology, Rigshospitalet, University Hospital of Copenhagen, Copenhagen, Denmark
| | | | - Anne Rogiers
- Department of Psychiatry, Brugmann University Hospital, Brussels, Belgium
| | - Bart Neyns
- Department of Medical Oncology, Universitair Ziekenhuis Brussel Oncologisch Centrum, Brussels, Belgium
| | - John B Haanen
- Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands
| | - Sandra A Mitchell
- Outcomes Research Branch, Healthcare Delivery Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, MD, USA
| | - Alfredo Addeo
- Department of Oncology, University Hospital of Geneva, Geneva, Switzerland
| | - Olivier Michielin
- Department of Oncology, Lausanne University Hospital (CHUV), Lausanne, Switzerland
| | - Manuela Eicher
- Department of Oncology, Lausanne University Hospital (CHUV), Lausanne, Switzerland; Institute of Higher Education and Research in Healthcare, Faculty of Biology and Medicine, University of Lausanne and Lausanne University Hospital, Lausanne, Switzerland.
| |
Collapse
|
3
|
Jankovic J, Da Silva Lopes AM, Morez A, Darnac C, Demicheli R, Dalla-Vale M, Lauriers N, Garcia Sanchez J, Bouchaab H, Ninane F, Peters S, Michielin O, Pradervand S, Eicher M, Colomer-Lahiguera S. [Telephone follow-up of SARS-CoV-2 positive patients at the Oncology Department of Lausanne University Hospital]. Rev Med Suisse 2021; 17:703-707. [PMID: 33830703] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/12/2023]
Abstract
Compared with the general population, oncology patients face a higher morbidity and mortality caused by the COVID-19 pandemic. As a result, health systems had to quickly adapt cancer care in order to maintain the best quality and patient safety. From March to May and from October to December 2020, 254 patients diagnosed with cancer and tested positive for SARS-CoV-2 benefited from a tele-health monitoring at the Oncology Department at CHUV. This article describes the key points of the development, implementation and operation of this tele-health monitoring, enabled by an interdisciplinary and inter-professional collaboration between different units and healthcare professionals.
Collapse
Affiliation(s)
- Jeremy Jankovic
- Service d'oncologie médicale, Département d'oncologie, CHUV, 1011 Lausanne
| | - André Manuel Da Silva Lopes
- Institut universitaire de formation et recherche en soins (IUFRS), Faculté de biologie et médecine, UNIL-CHUV, 1010 Lausanne
| | - Aurélie Morez
- Institut universitaire de formation et recherche en soins (IUFRS), Faculté de biologie et médecine, UNIL-CHUV, 1010 Lausanne
| | | | - Rita Demicheli
- Service d'oncologie médicale, Département d'oncologie, CHUV, 1011 Lausanne
| | - Margaux Dalla-Vale
- Centre d'oncologie de précision, Département d'oncologie, CHUV, 1011 Lausanne
| | - Nathalie Lauriers
- Service des thérapies expérimentales, Département d'oncologie, CHUV, 1011 Lausanne
| | - Javier Garcia Sanchez
- Institut universitaire de formation et recherche en soins (IUFRS), Faculté de biologie et médecine, UNIL-CHUV, 1010 Lausanne
| | - Hasna Bouchaab
- Service d'oncologie médicale, Département d'oncologie, CHUV, 1011 Lausanne
| | | | - Solange Peters
- Service d'oncologie médicale, Département d'oncologie, CHUV, 1011 Lausanne
| | - Olivier Michielin
- Service d'oncologie médicale, Département d'oncologie, CHUV, 1011 Lausanne
- Centre d'oncologie de précision, Département d'oncologie, CHUV, 1011 Lausanne
| | - Sylvain Pradervand
- Centre d'oncologie de précision, Département d'oncologie, CHUV, 1011 Lausanne
| | - Manuela Eicher
- Institut universitaire de formation et recherche en soins (IUFRS), Faculté de biologie et médecine, UNIL-CHUV, 1010 Lausanne
| | - Sara Colomer-Lahiguera
- Institut universitaire de formation et recherche en soins (IUFRS), Faculté de biologie et médecine, UNIL-CHUV, 1010 Lausanne
| |
Collapse
|